Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,925.50    2.50 (0.13%)
Bid:
1,931.50
Ask:
1,932.50
Spread: 1.00 (0.052%)
Market Cap: £77.17b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block listing Interim Review

15 Nov 2021 16:37

RNS Number : 4366S
GlaxoSmithKline PLC
15 November 2021
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 15 November 2021

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2021

To:

31 October 2021

Balance of unallotted securities under scheme(s) from previous return:

35,519

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

230,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

265,519

 

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2021

To:

31 October 2021

Balance of unallotted securities under scheme(s) from previous return:

382,466

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

3,000,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

313,319

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

3,069,147

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFZMMMVKKGMZM
Date   Source Headline
6th Sep 20247:00 amRNSPositive Phase III results for Nucala in COPD
2nd Sep 20243:00 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSEMA approval on Arexvy for 50-59 at risk
28th Aug 20247:10 amRNSSENKU Designation for Bepirovirsen in Japan
28th Aug 20247:05 amRNSNucala approved in Japan for use in CRSwNP
28th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20247:00 amRNSB7-H3 ADC US FDA Breakthrough Therapy Designation
16th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
12th Aug 20243:30 pmRNSDirector/PDMR Shareholding
6th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
2nd Aug 20247:00 amRNSFDA Expands Jemperli Approval
1st Aug 20243:00 pmRNSTotal Voting Rights
31st Jul 20247:00 amRNS2nd Quarter Results
29th Jul 20248:18 amRNSStatement: Zantac (ranitidine) litigation
29th Jul 20247:00 amRNSCHMP positive opinion on Arexvy for 50-59 at risk
19th Jul 202410:36 amRNSBlenrep EMA Filing Acceptance
18th Jul 20243:30 pmRNSDirector/PDMR Shareholding
16th Jul 20243:30 pmRNSDirector/PDMR Shareholding
15th Jul 20243:30 pmRNSDirector/PDMR Shareholding
12th Jul 20243:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20247:00 amRNSGSK and CureVac collaboration restructured
1st Jul 20243:00 pmRNSTotal Voting Rights
28th Jun 20245:37 pmRNSStatement: Zantac (ranitidine) litigation
24th Jun 20247:05 amRNSOmjjara approved in Japan for myelofibrosis
24th Jun 20247:00 amRNSEMA validates Jemperli marketing authorisation
21st Jun 20243:30 pmRNSDirector/PDMR Shareholding
12th Jun 20243:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
10th Jun 20246:27 pmRNSStatement: Zantac (ranitidine) litigation
10th Jun 20247:00 amRNSFDA approves Arexvy for adults 50-59 at risk
3rd Jun 20243:00 pmRNSTotal Voting Rights
3rd Jun 20241:03 pmRNSUnprecedented results in Jemperli trial continue
3rd Jun 20247:05 amRNSASCO positive Blenrep DREAMM-8 trial results
3rd Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
24th May 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st May 20247:00 amRNSPositive phase III asthma results for depemokimab
20th May 20243:30 pmRNSDirector/PDMR Shareholding
17th May 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th May 20244:42 pmRNSGSK announces intention to sell shares in Haleon
14th May 20243:30 pmRNSDirector/PDMR Shareholding
13th May 20243:00 pmRNSBlock listing Interim Review
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.